

Presymptomatic cognitive and neuroanatomical changes in prefrontal cortex in presymptomatic dementia in the Genetic Frontotemporal dementia Initiative analysis

Lancet Neurology, The
14, 253-262

DOI: [10.1016/s1474-4422\(14\)70324-2](https://doi.org/10.1016/s1474-4422(14)70324-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia?. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1065-1074.	1.2	59
2	Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease?. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 751-759.	1.2	34
3	C9ORF72 and the FTD-ALS spectrum: a systematic review of neuroimaging studies. <i>Dementia E Neuropsychologia</i> , 2015, 9, 413-421.	0.3	11
4	The Genetics of Monogenic Frontotemporal Dementia. <i>Dementia E Neuropsychologia</i> , 2015, 9, 219-229.	0.3	44
5	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 171.	1.7	90
6	Dementias show differential physiological responses to salient sounds. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 73.	1.0	21
7	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 291-301.	4.9	270
8	Frontotemporal dementia: a peek under its invisibility cloak. <i>Lancet Neurology</i> , The, 2015, 14, 236-237.	4.9	0
10	Brain morphologic changes in asymptomatic <i>C9orf72</i> repeat expansion carriers. <i>Neurology</i> , 2015, 85, 1780-1788.	1.5	66
11	Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. <i>Brain</i> , 2015, 138, 3360-3372.	3.7	90
12	Cortical hyperexcitability in patients with <i>C9ORF72</i> mutations: Relationship to phenotype. <i>Muscle and Nerve</i> , 2016, 54, 264-269.	1.0	29
13	What is the role of TDP-43 in <i>C9orf72</i> -related amyotrophic lateral sclerosis and frontotemporal dementia?. <i>Brain</i> , 2016, 139, 3057-3059.	3.7	7
14	Spectral and Shape Analysis in Medical Imaging. <i>Lecture Notes in Computer Science</i> , 2016, , ,	1.0	1
15	Genetics of Frontotemporal Lobar Degeneration: From the Bench to the Clinic. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1157-1176.	1.2	6
16	Longitudinal imaging in <i>C9orf72</i> mutation carriers: Relationship to phenotype. <i>NeuroImage: Clinical</i> , 2016, 12, 1035-1043.	1.4	64
17	Looking for Neuroimaging Markers in Frontotemporal Lobar Degeneration Clinical Trials: A Multi-Voxel Pattern Analysis Study in Granulin Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 249-262.	1.2	39
18	A physiological signature of sound meaning in dementia. <i>Cortex</i> , 2016, 77, 13-23.	1.1	18
19	<i>C9orf72</i> mutations and the puzzle of cerebro-cerebellar network degeneration. <i>Brain</i> , 2016, 139, e44-e44.	3.7	1

#	ARTICLE	IF	CITATIONS
20	Reply:C9orf72mutations and the puzzle of cerebro-cerebellar network degeneration. <i>Brain</i> , 2016, 139, e45-e45.	3.7	0
21	Advances in neuroimaging in frontotemporal dementia. <i>Journal of Neurochemistry</i> , 2016, 138, 193-210.	2.1	75
22	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2016, 79, 152-158.	2.8	188
23	Genetics of <scp>FTLD</scp>: overview and what else we can expect from genetic studies. <i>Journal of Neurochemistry</i> , 2016, 138, 32-53.	2.1	118
24	Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions. <i>Journal of Neurochemistry</i> , 2016, 138, 145-162.	2.1	59
25	The clinical spectrum of sporadic and familial forms of frontotemporal dementia. <i>Journal of Neurochemistry</i> , 2016, 138, 6-31.	2.1	111
26	Charting Frontotemporal Dementia: From Genes to Networks. <i>Journal of Neuroimaging</i> , 2016, 26, 16-27.	1.0	9
28	Genetics of Frontotemporal Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 107.	2.0	100
29	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 623-636.	1.7	207
30	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. <i>Neurology</i> , 2016, 87, 1329-1336.	1.5	354
31	Presymptomatic cognitive decline in familial frontotemporal dementia. <i>Neurology</i> , 2016, 87, 384-391.	1.5	42
32	Impaired long-term potentiation-like cortical plasticity in presymptomatic genetic frontotemporal dementia. <i>Annals of Neurology</i> , 2016, 80, 472-476.	2.8	48
33	Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal Dementia. , 2016, , 533-546.		1
34	Behavioral Variant Frontotemporal Dementia. <i>JAMA Neurology</i> , 2016, 73, 1051.	4.5	0
35	Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. <i>Brain</i> , 2016, 139, 3202-3216.	3.7	136
36	Expanding the phenotypic associations of globular glial tau subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 6-13.	1.2	23
37	Targeting tauopathies for therapeutic translation. <i>Nature Reviews Neurology</i> , 2016, 12, 74-76.	4.9	21
38	The habenula: an under-recognised area of importance in frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 910-912.	0.9	14

#	ARTICLE	IF	CITATIONS
39	Patterns of regional cerebellar atrophy in genetic frontotemporal dementia. <i>NeuroImage: Clinical</i> , 2016, 11, 287-290.	1.4	54
40	Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. <i>Journal of Neurology</i> , 2016, 263, 558-574.	1.8	40
41	Loss of exosomes in progranulin-associated frontotemporal dementia. <i>Neurobiology of Aging</i> , 2016, 40, 41-49.	1.5	47
42	An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. <i>Current Opinion in Neurobiology</i> , 2016, 36, 99-106.	2.0	59
43	Clinical and neuroimaging characterization of two C9orf72-positive siblings with amyotrophic lateral sclerosis and schizophrenia. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 297-300.	1.1	3
44	Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies. <i>Molecular Neurobiology</i> , 2016, 53, 6091-6105.	1.9	11
45	Key emerging issues in frontotemporal dementia. <i>Journal of Neurology</i> , 2016, 263, 407-413.	1.8	3
46	The clinical, neuroanatomical, and neuropathologic phenotype of <i>TBK1</i> -associated frontotemporal dementia: A longitudinal case report. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 75-81.	1.2	28
47	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	2.9	23
48	Neuropsychiatric Symptoms in Mild Cognitive Impairment. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 161-169.	0.9	84
49	Psychiatric Presentations of <i>C9orf72</i> Mutation: What Are the Diagnostic Implications for Clinicians?. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 195-205.	0.9	58
50	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.4	58
51	Frontotemporal dementia. , 2017, , 199-249.		1
52	Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. <i>Acta Neuropathologica</i> , 2017, 134, 241-254.	3.9	99
53	Poly ϵ -GP in cerebrospinal fluid links <i>C9orf72</i> -associated dipeptide repeat expression to the asymptomatic phase of \langle ALS \rangle / \langle FTD \rangle . <i>EMBO Molecular Medicine</i> , 2017, 9, 859-868.	3.3	90
54	von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 701-709.	1.2	30
55	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2017, 140, 1784-1791.	3.7	55
56	The TMEM106B risk allele is associated with lower cortical volumes in a clinically diagnosed frontotemporal dementia cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 997-998.	0.9	9

#	ARTICLE	IF	CITATIONS
57	Imaging and fluid biomarkers in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2017, 13, 406-419.	4.9	163
58	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. <i>NeuroImage: Clinical</i> , 2017, 15, 171-180.	1.4	63
59	Structural and functional brain signatures of C9orf72 in motor neuron disease. <i>Neurobiology of Aging</i> , 2017, 57, 206-219.	1.5	54
60	Disease progression in C9orf72 mutation carriers. <i>Neurology</i> , 2017, 89, 234-241.	1.5	29
61	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	179
62	Antibodies inhibit transmission and aggregation of C9orf72 poly(GA) dipeptide repeat proteins. <i>EMBO Molecular Medicine</i> , 2017, 9, 687-702.	3.3	70
63	Mapping Neurodegenerative Disease Onset and Progression. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a023622.	2.3	67
64	Longitudinal Executive Function and Episodic Memory Profiles in Behavioral-Variant Frontotemporal Dementia and Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 34-43.	1.2	63
65	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 153-174.	1.1	607
67	Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. <i>NeuroImage: Clinical</i> , 2017, 14, 286-297.	1.4	129
68	Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies. <i>European Journal of Pharmacology</i> , 2017, 817, 76-85.	1.7	9
69	Auditory conflict and congruence in frontotemporal dementia. <i>Neuropsychologia</i> , 2017, 104, 144-156.	0.7	12
70	Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. <i>Brain</i> , 2017, 140, 3081-3104.	3.7	109
71	Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. <i>Neurology</i> , 2017, 89, 1256-1264.	1.5	82
72	Modifiers of GRN -Associated Frontotemporal Lobar Degeneration. <i>Trends in Molecular Medicine</i> , 2017, 23, 962-979.	3.5	26
73	Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 164-175.	1.3	11
74	Emerging Diagnostic and Therapeutic Strategies for Tauopathies. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 72.	2.0	31
75	Advances in Neuroimaging for Neurodegenerative Disease. <i>Advances in Neurobiology</i> , 2017, 15, 451-478.	1.3	5

#	ARTICLE	IF	CITATIONS
76	Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 11-23.	2.1	72
77	Behavior Symptoms in Primary Progressive Aphasia Variants. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2017, , 27-43.	0.3	1
78	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 753-760.	1.2	26
79	Neuroimaging in dementia. , 0, , 19-43.		0
80	Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. <i>Human Molecular Genetics</i> , 2017, 26, ddx003.	1.4	22
81	Localized vs. Systematic Neurodegeneration: A Paradigm Shift in Understanding Neurodegenerative Diseases. <i>Frontiers in Systems Neuroscience</i> , 2017, 11, 62.	1.2	9
82	Diagnosing, monitoring and managing behavioural variant frontotemporal dementia. <i>Medical Journal of Australia</i> , 2017, 207, 303-308.	0.8	16
83	EEG power at 3Âmonths in infants at high familial risk for autism. <i>Journal of Neurodevelopmental Disorders</i> , 2017, 9, 34.	1.5	63
84	Epilepsy at the prodromal stages of neurodegenerative diseases. <i>Psychologie & Neuropsychiatrie Du Vieillessement</i> , 2017, 15, 75-82.	0.2	12
85	Thalamic atrophy in frontotemporal dementia â€” Not just a C9orf72 problem. <i>NeuroImage: Clinical</i> , 2018, 18, 675-681.	1.4	53
86	Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1467-1480.	1.2	47
87	Poly(GP), neurofilament and grey matter deficits in <i>C9orf72</i> expansion carriers. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 583-597.	1.7	48
88	Decreased Prefrontal Activation during Matrix Reasoning in Predementia Progranulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 583-589.	1.2	5
89	Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia. <i>Journal of Neurology</i> , 2018, 265, 1381-1392.	1.8	49
90	Cardiac responses to viewing facial emotion differentiate frontotemporal dementias. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 687-696.	1.7	23
91	RNA versus protein toxicity in C9orf72 ALS/FTLD. <i>Acta Neuropathologica</i> , 2018, 135, 475-479.	3.9	8
92	Plasma tau is increased in frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 804-807.	0.9	41
93	Neurotransmitter deficits from frontotemporal lobar degeneration. <i>Brain</i> , 2018, 141, 1263-1285.	3.7	129

#	ARTICLE	IF	CITATIONS
94	Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. <i>Brain Imaging and Behavior</i> , 2018, 12, 1696-1707.	1.1	89
95	Early Cognitive, Structural, and Microstructural Changes in Presymptomatic <i>C9orf72</i> Carriers Younger Than 40 Years. <i>JAMA Neurology</i> , 2018, 75, 236.	4.5	108
96	Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in <i>MAPT</i> mutation carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 449-455.	0.9	31
97	Neuroanatomical Correlates of Transcranial Magnetic Stimulation in Presymptomatic Granulin Mutation Carriers. <i>Brain Topography</i> , 2018, 31, 488-497.	0.8	21
98	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	3.7	114
99	Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 131-140.	1.9	41
100	Longitudinal diffusion imaging across the <i>C9orf72</i> clinical spectrum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 53-60.	0.9	44
101	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 191-196.	1.5	151
102	Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1113-1123.	1.2	29
103	Cerebrospinal fluid in the dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 85-97.	1.0	9
104	Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. <i>Neurobiology of Aging</i> , 2018, 62, 244.e9-244.e13.	1.5	30
105	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 245.e9-245.e12.	1.5	40
106	Frontotemporal dementia: latest evidence and clinical implications. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 33-48.	1.2	102
107	Brain structural alterations are distributed following functional, anatomic and genetic connectivity. <i>Brain</i> , 2018, 141, 3211-3232.	3.7	61
108	Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in <i>C9orf72</i> . <i>Frontiers in Neurology</i> , 2018, 9, 1063.	1.1	28
109	A <i>C6orf10/LOC101929163</i> locus is associated with age of onset in <i>C9orf72</i> carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
110	Thalamic Nuclei Segmentation Using Tractography, Population-Specific Priors and Local Fibre Orientation. <i>Lecture Notes in Computer Science</i> , 2018, , 383-391.	1.0	4
111	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. <i>Nature Communications</i> , 2018, 9, 4273.	5.8	263

#	ARTICLE	IF	CITATIONS
112	Morphometric MRI as a diagnostic biomarker of frontotemporal dementia: A systematic review to determine clinical applicability. <i>NeuroImage: Clinical</i> , 2018, 20, 685-696.	1.4	32
113	Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. <i>NeuroImage: Clinical</i> , 2018, 18, 591-598.	1.4	26
114	Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. <i>NeuroImage: Clinical</i> , 2018, 19, 497-506.	1.4	21
115	Asymmetry of Hippocampus and Amygdala Defect in Subjective Cognitive Decline Among the Community Dwelling Chinese. <i>Frontiers in Psychiatry</i> , 2018, 9, 226.	1.3	71
116	Phenotypic Heterogeneity in Dementia: A Challenge for Epidemiology and Biomarker Studies. <i>Frontiers in Public Health</i> , 2018, 6, 181.	1.3	55
117	Genetic risk for neurodegenerative disorders, and its overlap with cognitive ability and physical function. <i>PLoS ONE</i> , 2018, 13, e0198187.	1.1	17
118	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 46.	3.0	34
119	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 45.	1.7	40
120	Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis – Frontotemporal Spectrum Disorder (ALS-FTSD). A Review. <i>Frontiers in Neuroscience</i> , 2018, 12, 259.	1.4	24
121	Hippocampal Subfield Volumetry: Differential Pattern of Atrophy in Different Forms of Genetic Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 497-504.	1.2	26
122	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1025-1036.	1.7	39
123	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1-16.	1.2	28
124	MRI of non-Alzheimer's dementia: current and emerging knowledge. <i>Current Opinion in Neurology</i> , 2018, 31, 405-414.	1.8	10
125	Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI. <i>NeuroImage: Clinical</i> , 2018, 20, 188-196.	1.4	15
127	Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias. <i>Focus (American Journal of Psychiatry)</i> , 2018, 175, 1000-1006.	0.4	6
128	Clinical trials. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 153, 431-444.	1.0	6
129	Progranulin as a therapeutic target for dementia. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 579-585.	1.5	17
130	Primary Care Mental Health in Older People. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
131	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.		2
132	Rates of lobar atrophy in asymptomatic <i>MAPT</i> mutation carriers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 338-346.	1.8	22
133	The functional neuroanatomy of emotion processing in frontotemporal dementias. <i>Brain</i> , 2019, 142, 2873-2887.	3.7	45
134	Neuroinflammation in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2019, 15, 540-555.	4.9	159
135	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. <i>Frontiers in Neuroscience</i> , 2019, 13, 757.	1.4	22
136	Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy. <i>Neuron</i> , 2019, 104, 856-868.e5.	3.8	85
137	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	4.9	128
138	Predementia Brain Changes in Progranulin Mutation: A Systematic Review of Neuroimaging Evidence. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 1-18.	0.7	2
139	Clinical and neuroimaging profiles to identify C9orf72 ϵ FTD patients and serum Neurofilament to monitor the progression and the severity of the disease. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 326-333.	0.2	1
140	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	1.5	14
141	Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. <i>Brain</i> , 2019, 142, 760-770.	3.7	16
142	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. <i>Brain</i> , 2019, 142, 443-459.	3.7	65
143	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. <i>Translational Psychiatry</i> , 2019, 9, 54.	2.4	28
144	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	2.1	33
145	An update on genetic frontotemporal dementia. <i>Journal of Neurology</i> , 2019, 266, 2075-2086.	1.8	253
146	Cellular and regional vulnerability in frontotemporal tauopathies. <i>Acta Neuropathologica</i> , 2019, 138, 705-727.	3.9	49
147	A multimodal MRI-based classification signature emerges just prior to symptom onset in frontotemporal dementia mutation carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1207-1214.	0.9	18
148	Naming and conceptual understanding in frontotemporal dementia. <i>Cortex</i> , 2019, 120, 22-35.	1.1	19

#	ARTICLE	IF	CITATIONS
149	Prodromal and Early bvFTD: Evaluating Clinical Features and Current Biomarkers. <i>Frontiers in Neuroscience</i> , 2019, 13, 658.	1.4	10
150	Psychological and Cognitive Markers of Behavioral Variant Frontotemporal Dementia—A Clinical Neuropsychologist's View on Diagnostic Criteria and Beyond. <i>Frontiers in Neurology</i> , 2019, 10, 594.	1.1	67
151	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenocopy in Mapt Mutation Carriers. <i>Journal of Neuroimaging</i> , 2019, 29, 624-629.	1.0	9
152	Presymptomatic spinal cord pathology in <i>C9orf72</i> mutation carriers: A longitudinal neuroimaging study. <i>Annals of Neurology</i> , 2019, 86, 158-167.	2.8	71
153	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	0.9	23
154	Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies. <i>Brain</i> , 2019, 142, 2068-2081.	3.7	30
155	Gyrification abnormalities in presymptomatic <i>C9orf72</i> expansion carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1005-1010.	0.9	24
156	Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 698-707.	1.7	42
157	White Matter Damage in the Semantic Variant of Primary Progressive Aphasia. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 373-382.	0.3	8
158	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	3.7	45
160	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. <i>NeuroImage: Clinical</i> , 2019, 22, 101751.	1.4	30
161	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2019, 142, 1108-1120.	3.7	41
162	In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 373-378.	1.7	27
163	Frontotemporal Dementia: A Clinical Review. <i>Seminars in Neurology</i> , 2019, 39, 251-263.	0.5	47
164	Brain Connectivity and Information-Flow Breakdown Revealed by a Minimum Spanning Tree-Based Analysis of MRI Data in Behavioral Variant Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2019, 13, 211.	1.4	25
165	Amygdala subnuclei are differentially affected in the different genetic and pathological forms of frontotemporal dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 136-141.	1.2	17
166	Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2019, 76, 115-124.	1.5	59
167	Anxiety and Depression as Risk Factors in Frontotemporal Dementia and Alzheimer's Disease: The HUNT Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 414-425.	0.6	18

#	ARTICLE	IF	CITATIONS
168	Personalized TMS: role of RNA genotyping. <i>Mental Illness</i> , 2019, 11, 8-15.	0.8	1
169	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. <i>Neurology</i> , 2019, 93, e1699-e1706.	1.5	19
170	Links Between the C9orf72 Repeat Expansion and Psychiatric Symptoms. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 93.	2.0	18
171	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	1.4	27
172	Schizophrenia Phenotype Preceding Behavioral Variant Frontotemporal Dementia Related to C9orf72 Repeat Expansion. <i>Cognitive and Behavioral Neurology</i> , 2019, 32, 120-123.	0.5	12
173	Sleep symptoms in syndromes of frontotemporal dementia and Alzheimer's disease: A proof-of-principle behavioural study. <i>ENeurologicalSci</i> , 2019, 17, 100212.	0.5	17
174	Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. <i>Brain</i> , 2019, 142, 193-208.	3.7	73
175	Review: Clinical, genetic and neuroimaging features of frontotemporal dementia. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 6-18.	1.8	32
176	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. <i>NeuroImage</i> , 2019, 188, 282-290.	2.1	16
177	Multimodal imaging in familial FTL: phenoconversion and planning for the future. <i>Brain</i> , 2019, 142, 8-11.	3.7	18
178	Predictors of survival and progression in behavioural variant frontotemporal dementia. <i>European Journal of Neurology</i> , 2019, 26, 774-779.	1.7	22
179	Biomarkers for diseases with TDP-43 pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 43-59.	1.0	38
180	Cognitive Indicators of Preclinical Behavioral Variant Frontotemporal Dementia in <i>MAPT</i> Carriers. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 184-194.	1.2	24
181	Review: Fluid biomarkers for frontotemporal dementias. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 81-87.	1.8	35
182	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	1.5	47
183	Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 76, 133-140.	1.5	39
184	Neurite density is reduced in the presymptomatic phase of <i>C9orf72</i> disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 387-394.	0.9	50
185	C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. <i>Acta Neuropathologica</i> , 2019, 137, 1-26.	3.9	53

#	ARTICLE	IF	CITATIONS
186	Longitudinal Neuropsychological Study of Presymptomatic c.709-1G>A Progranulin Mutation Carriers. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 39-47.	1.2	7
187	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€€EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.4	32
188	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.4	38
189	Thalamic nuclei in frontotemporal dementia: Mediodorsal nucleus involvement is universal but pulvinar atrophy is unique to C9orf72. <i>Human Brain Mapping</i> , 2020, 41, 1006-1016.	1.9	44
190	Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure. <i>Neurobiology of Aging</i> , 2020, 86, 143-155.	1.5	34
191	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. <i>Alzheimer's and Dementia</i> , 2020, 16, 22-36.	0.4	32
192	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	4.9	175
193	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 49-59.	0.4	27
194	Longitudinal (¹⁸F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 106-108.	0.9	8
195	Lower urinary tract function in frontotemporal lobar degeneration: A preliminary observation. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2020, 229, 102719.	1.4	3
196	Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2020, 145, 105063.	2.1	23
197	Longitudinal changes in resting state networks in early presymptomatic carriers of C9orf72 expansions. <i>NeuroImage: Clinical</i> , 2020, 28, 102354.	1.4	9
198	Neurodegenerative Disorders of Speech and Language: Non-language-dominant Diseases. , 2022, , 66-80.		4
199	Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. <i>Brain Communications</i> , 2020, 2, fcaa126.	1.5	3
200	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	0.9	25
201	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	0.9	12
202	Microglial burden, activation and dystrophy patterns in frontotemporal lobar degeneration. <i>Journal of Neuroinflammation</i> , 2020, 17, 234.	3.1	29
203	Towards accurate and unbiased imaging-based differentiation of Parkinsonâ€™s disease, progressive supranuclear palsy and corticobasal syndrome. <i>Brain Communications</i> , 2020, 2, fcaa051.	1.5	14

#	ARTICLE	IF	CITATIONS
204	GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. <i>Brain</i> , 2020, 143, 3449-3462.	3.7	55
205	Classification using fractional anisotropy predicts conversion in genetic frontotemporal dementia, a proof of concept. <i>Brain Communications</i> , 2020, 2, fcaa079.	1.5	3
206	The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?. <i>Journal of Neurology</i> , 2021, 268, 4607-4629.	1.8	28
207	The neurophysiological architecture of semantic dementia: spectral dynamic causal modelling of a neurodegenerative proteinopathy. <i>Scientific Reports</i> , 2020, 10, 16321.	1.6	16
208	Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia. <i>Ageing Research Reviews</i> , 2020, 64, 101172.	5.0	5
209	Deficits in verbal fluency in presymptomatic <i>C9orf72</i> mutation gene carriers—a developmental disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1195-1200.	0.9	42
210	Finding specificity in structural brain alterations through Bayesian reverse inference. <i>Human Brain Mapping</i> , 2020, 41, 4155-4172.	1.9	17
211	Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics. <i>Frontiers in Neurology</i> , 2020, 11, 599384.	1.1	16
212	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. <i>JAMA Network Open</i> , 2020, 3, e2022847.	2.8	19
213	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of <i>C9orf72</i> Repeat Expansion. <i>JAMA Neurology</i> , 2020, 77, 1008.	4.5	45
214	Structural Brain Changes in Pre-Clinical FTD MAPT Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 595-606.	1.2	10
215	Transcranial stimulation in frontotemporal dementia: A randomized, double-blind, sham-controlled trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12033.	1.8	27
216	Congenetic expression of poly-GA but not poly-PR in mice triggers selective neuron loss and interferon responses found in C9orf72 ALS. <i>Acta Neuropathologica</i> , 2020, 140, 121-142.	3.9	44
217	DNA methylation age acceleration is associated with ALS age of onset and survival. <i>Acta Neuropathologica</i> , 2020, 139, 943-946.	3.9	30
218	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. <i>Frontiers in Neurology</i> , 2020, 11, 80.	1.1	13
219	Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. <i>Neurobiology of Aging</i> , 2020, 91, 167.e1-167.e9.	1.5	24
220	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. <i>Brain</i> , 2020, 143, 1632-1650.	3.7	158
221	Neurological update: neuroimaging in dementia. <i>Journal of Neurology</i> , 2020, 267, 3429-3435.	1.8	11

#	ARTICLE	IF	CITATIONS
222	Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. <i>Translational Neurodegeneration</i> , 2020, 9, 27.	3.6	23
223	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	1.5	42
224	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	0.7	18
225	Cognitive inhibition impairments in presymptomatic <i>C9orf72</i> carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 366-372.	0.9	14
226	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2020, 88, 42-50.	1.5	14
227	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	0.9	106
228	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. <i>Alzheimer's and Dementia</i> , 2020, 16, 71-78.	0.4	33
229	Imaging biomarkers in neurodegeneration: current and future practices. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 49.	3.0	96
230	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	0.9	55
231	Genetic forms of frontotemporal lobar degeneration: Current diagnostic approach and new directions in therapeutic strategies. <i>Revue Neurologique</i> , 2020, 176, 571-581.	0.6	9
232	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	2.8	19
233	Genetic testing in dementia – utility and clinical strategies. <i>Nature Reviews Neurology</i> , 2021, 17, 23-36.	4.9	26
234	Hyperconnectivity in Dementia Is Early and Focal and Wanes with Progression. <i>Cerebral Cortex</i> , 2021, 31, 97-105.	1.6	18
235	Emotion recognition of morphed facial expressions in presymptomatic and symptomatic frontotemporal dementia, and Alzheimer's dementia. <i>Journal of Neurology</i> , 2021, 268, 102-113.	1.8	15
236	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. <i>Movement Disorders</i> , 2021, 36, 503-508.	2.2	15
237	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	1.7	21
238	Longitudinal changes in network homogeneity in presymptomatic <i>C9orf72</i> mutation carriers. <i>Neurobiology of Aging</i> , 2021, 99, 1-10.	1.5	5
239	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.4	36

#	ARTICLE	IF	CITATIONS
240	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.4	31
241	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12185.	1.2	11
242	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. <i>Brain</i> , 2022, 145, 1079-1097.	3.7	30
243	Looking beneath the surface: the importance of subcortical structures in frontotemporal dementia. <i>Brain Communications</i> , 2021, 3, fcab158.	1.5	22
244	The Frontotemporal Dementia Prevention Initiative: Linking Together Genetic Frontotemporal Dementia Cohort Studies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 113-121.	0.8	3
245	Frontotemporal Lobar Degeneration. , 2021, , 61-89.		0
246	The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development. <i>Brain Imaging and Behavior</i> , 2021, 15, 2693-2719.	1.1	15
247	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	2.8	42
248	Clinical and Neuroimaging Aspects of Familial Frontotemporal Lobar Degeneration Associated with MAPT and GRN Mutations. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 77-92.	0.8	3
249	Modelling the cascade of biomarker changes in <i>GRN</i>-related frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 494-501.	0.9	27
250	Neuroimaging in Frontotemporal Lobar Degeneration: Research and Clinical Utility. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 93-112.	0.8	5
251	Advances in neuroimaging to support translational medicine in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 263-270.	0.9	12
252	Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 42.	3.0	13
253	The Role of White Matter Dysfunction and Leukoencephalopathy/Leukodystrophy Genes in the Aetiology of Frontotemporal Dementias: Implications for Novel Approaches to Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2541.	1.8	7
254	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	0.9	10
255	Cognitive dysfunction in amyotrophic lateral sclerosis: can we predict it?. <i>Neurological Sciences</i> , 2021, 42, 2211-2222.	0.9	16
256	Early life involvement in C9orf72 repeat expansion carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 93-100.	0.9	16
257	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. <i>Neurotherapeutics</i> , 2021, 18, 728-752.	2.1	30

#	ARTICLE	IF	CITATIONS
258	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2021, 151, 105247.	2.1	3
259	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.5	52
260	MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. <i>Brain Communications</i> , 2021, 3, fcb114.	1.5	11
261	Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. <i>CNS Drugs</i> , 2021, 35, 483-505.	2.7	13
263	Ataxin-2 gene: a powerful modulator of neurological disorders. <i>Current Opinion in Neurology</i> , 2021, 34, 578-588.	1.8	12
264	Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. <i>Lancet Neurology</i> , The, 2021, 20, 373-384.	4.9	35
265	Infratentorial pathology in frontotemporal dementia: cerebellar grey and white matter alterations in FTD phenotypes. <i>Journal of Neurology</i> , 2021, 268, 4687-4697.	1.8	16
266	Characterizing the Clinical Features and Atrophy Patterns of <i>MAPT</i> -Related Frontotemporal Dementia With Disease Progression Modeling. <i>Neurology</i> , 2021, 97, e941-e952.	1.5	29
267	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. <i>Frontiers in Neurology</i> , 2021, 12, 679927.	1.1	6
268	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. <i>Cortex</i> , 2021, 139, 99-115.	1.1	12
269	Synaptic density in carriers of C9orf72 mutations: a [¹¹ C]UCBâ€ PET study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1515-1523.	1.7	27
270	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	3.0	12
272	Plasma NfL levels and longitudinal change rates in <i>C9orf72</i> and <i>GRN</i> -associated diseases: from tailored references to clinical applications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1278-1288.	0.9	25
273	Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging. <i>Frontiers in Neurology</i> , 2021, 12, 723450.	1.1	16
274	MRI characterization of rat brain aging at structural and functional level: Clues for translational applications. <i>Experimental Gerontology</i> , 2021, 152, 111432.	1.2	2
275	Differential Lipid Mediator Involvement in the Different Forms of Genetic Frontotemporal Dementia: Novel Insights into Neuroinflammation. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 283-289.	1.2	1
276	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	1.5	3
277	Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S <i>MAPT</i> Mutation Carrier. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1017-1023.	1.2	1

#	ARTICLE	IF	CITATIONS
278	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. <i>Clinical Neurophysiology</i> , 2021, 132, 2568-2607.	0.7	85
279	Primary progressive aphasia associated with C9orf72 expansions: Another side of the story. <i>Cortex</i> , 2021, 145, 145-159.	1.1	9
280	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	1.4	28
281	FDG-PET in presymptomatic C9orf72 mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 31, 102687.	1.4	16
282	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	1.4	8
283	Behavioral variant of frontotemporal dementia. , 2021, , 303-347.		0
284	Spatio-Temporal Shape Analysis of Cross-Sectional Data for Detection of Early Changes in Neurodegenerative Disease. <i>Lecture Notes in Computer Science</i> , 2016, , 63-75.	1.0	4
285	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	1.1	26
286	Brain-behaviour associations and neural representations of emotions in frontotemporal dementia. <i>Brain</i> , 2020, 143, e17-e17.	3.7	8
287	Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. <i>Brain</i> , 2020, 143, 1555-1571.	3.7	94
295	Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 533-538.	0.7	7
296	Frontotemporal Dementias. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 464-489.	0.4	48
297	Behavioral Variant Frontotemporal Dementia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 76-100.	0.4	23
298	Recent advances in understanding frontotemporal degeneration. <i>F1000Research</i> , 2019, 8, 2098.	0.8	16
299	Neurotrophic effects of progranulin in vivo in reversing motor neuron defects caused by over or under expression of TDP-43 or FUS. <i>PLoS ONE</i> , 2017, 12, e0174784.	1.1	18
300	Preclinical progression of neurodegenerative diseases. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 289-298.	0.6	32
301	Proteomics and C9orf72 neuropathology identify ribosomes as poly-GR/PR interactors driving toxicity. <i>Life Science Alliance</i> , 2018, 1, e201800070.	1.3	88
302	A comparison of automated atrophy measures across the frontotemporal dementia spectrum: Implications for trials. <i>NeuroImage: Clinical</i> , 2021, 32, 102842.	1.4	2

#	ARTICLE	IF	CITATIONS
303	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	3.0	35
304	Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia. Brain Communications, 2021, 3, fcab241.	1.5	3
305	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	3.7	38
306	Early-Onset Frontotemporal Dementia-Related Semantic Variant of Primary Progressive Aphasia. Clinical Nuclear Medicine, 2022, 47, 260-264.	0.7	2
307	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
309	Autosomal Dominant Frontotemporal Lobar Degeneration: From Genotype to Phenotype. , 2018, , 123-145.		0
312	Reply: Brain-behaviour associations and neural representations of emotions in frontotemporal dementia. Brain, 2020, 143, e18-e18.	3.7	0
314	Voxel-Based Morphometry in Frontotemporal Dementia. Human Physiology, 2020, 46, 912-920.	0.1	0
315	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
316	Studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7-T magnetic resonance. European Radiology Experimental, 2021, 5, 36.	1.7	2
318	Biomarkers for C9orf7-ALS in Symptomatic and Pre-symptomatic Patients: State-of-the-art in the New Era of Clinical Trials. Journal of Neuromuscular Diseases, 2022, 9, 25-37.	1.1	11
319	Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188.	3.0	8
320	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
321	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	1.2	4
323	Studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7-T magnetic resonance. European Radiology Experimental, 2021, 5, 36.	1.7	10
324	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
325	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3
326	Six generations of <i>CHMP2B</i>-mediated Frontotemporal Dementia: Clinical features, predictive testing, progression, and survival. Acta Neurologica Scandinavica, 2022, 145, 529-540.	1.0	4

#	ARTICLE	IF	CITATIONS
328	Prediagnostic Progressive Supranuclear Palsy “ Insights from the UK Biobank. Parkinsonism and Related Disorders, 2022, 95, 59-64.	1.1	7
329	Cortical microstructure in primary progressive aphasia: a multicenter study. Alzheimer's Research and Therapy, 2022, 14, 27.	3.0	10
330	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
331	Data-driven staging of genetic frontotemporal dementia using multi-modal MRI. Human Brain Mapping, 2022, 43, 1821-1835.	1.9	7
332	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
333	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
334	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 2023, 146, 321-336.	3.7	30
335	The CBI detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
336	Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurology, The, 2022, 21, 258-272.	4.9	63
337	The changing landscape of neuroimaging in frontotemporal lobar degeneration: from group-level observations to single-subject data interpretation. Expert Review of Neurotherapeutics, 2022, 22, 179-207.	1.4	8
338	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. Alzheimer's and Dementia, 2023, 19, 226-243.	0.4	15
339	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
341	Brainstem atrophy is linked to extrapyramidal symptoms in frontotemporal dementia. Journal of Neurology, 2022, 269, 4488-4497.	1.8	2
342	Focal thalamus pathology in frontotemporal dementia: Phenotype-associated thalamic profiles. Journal of the Neurological Sciences, 2022, 436, 120221.	0.3	12
347	Functional Imaging for Neurodegenerative Diseases. Presse Medicale, 2022, 51, 104121.	0.8	3
348	How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases. Revue Neurologique, 2022, 178, 426-436.	0.6	2
349	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
350	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.000000000200582.	1.5	0

#	ARTICLE	IF	CITATIONS
351	Recent Advances in Frontotemporal Dementia. Canadian Journal of Neurological Sciences, 2023, 50, 485-494.	0.3	2
352	Fractal dimension of the brain in neurodegenerative disease and dementia: A systematic review. Ageing Research Reviews, 2022, 79, 101651.	5.0	20
353	Resting state functional brain networks associated with emotion processing in frontotemporal lobar degeneration. Molecular Psychiatry, 2022, 27, 4809-4821.	4.1	4
354	Behavioral Variant Frontotemporal Dementia. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 702-725.	0.4	3
355	Evidence of cerebellar TDP-43 loss of function in FTLD-TDP. Acta Neuropathologica Communications, 2022, 10, .	2.4	6
356	Hierarchical spectral clustering reveals brain size and shape changes in asymptomatic carriers of <i>C9orf72</i> . Brain Communications, 2022, 4, .	1.5	1
357	A longitudinal 18F-FDG PET/MRI study in asymptomatic stage of genetic Creutzfeldt-Jakob disease linked to G114V mutation. Journal of Neurology, 0, , .	1.8	0
358	The New Zealand Genetic Frontotemporal Dementia Study (FTDGeNZ): a longitudinal study of pre-symptomatic biomarkers. Journal of the Royal Society of New Zealand, 2023, 53, 511-531.	1.0	1
359	Study protocol: computerised cognitive testing in a cohort of people with frontotemporal dementia. BMJ Open, 2022, 12, e055211.	0.8	0
360	Pre-symptomatic radiological changes in frontotemporal dementia: propagation characteristics, predictive value and implications for clinical trials. Brain Imaging and Behavior, 2022, 16, 2755-2767.	1.1	4
361	Frequency and Longitudinal Course of Motor Signs In Genetic Frontotemporal Dementia. Neurology, 0, , 10.1212/WNL.0000000000200828.	1.5	3
362	Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2022, 442, 120415.	0.3	2
363	Disease Progression Score Estimation From Multimodal Imaging and MicroRNA Data Using Supervised Variational Autoencoders. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 6024-6035.	3.9	4
364	Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling. NeuroImage: Clinical, 2022, 36, 103144.	1.4	1
365	Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia. Alzheimer's Research and Therapy, 2022, 14, .	3.0	8
366	Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study. Journal of Neuroinflammation, 2022, 19, .	3.1	14
368	Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nature Medicine, 2022, 28, 2194-2206.	15.2	35
369	Early Motor Changes in Genetic Frontotemporal Dementia. Neurology, 2022, 99, 409-410.	1.5	0

#	ARTICLE	IF	CITATIONS
370	The Emerging Role of AI in Dementia Research and Healthcare. <i>Brain Informatics and Health</i> , 2022, , 95-106.	0.1	0
371	Longitudinal Brain Atrophy Rates in Presymptomatic Carriers of Genetic Frontotemporal Dementia. <i>Neurology</i> , 2022, 99, .	1.5	4
372	<sc>CSF</sc> glial markers are elevated in a subset of patients with genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1764-1777.	1.7	4
373	Dissecting the Many Faces of Frontotemporal Dementia: An Imaging Perspective. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12867.	1.8	1
374	Foreseeing Before Disease Onset. <i>Neurology</i> , 2022, 99, 1077-1078.	1.5	0
375	Brain Metabolic Profile in Presymptomatic <i>GRN</i> Carriers Throughout a 5-Year Follow-up. <i>Neurology</i> , 2023, 100, .	1.5	5
376	<sc>MicroRNA</sc> signatures in genetic frontotemporal dementia and amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1778-1791.	1.7	4
377	Common neural substrates of diverse neurodevelopmental disorders. <i>Brain</i> , 2023, 146, 438-447.	3.7	6
378	Development of a functional composite for the evaluation of spinal and bulbar muscular atrophy. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
379	Preâ€diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2023, 19, 1752-1763.	0.4	14
381	Synaptic Loss in Frontotemporal Dementia Revealed by [¹¹ C] <sc>UCBâ€</sc> Positron Emission Tomography</sc>. <i>Annals of Neurology</i> , 2023, 93, 142-154.	2.8	9
382	Temporal dynamics predict symptom onset and cognitive decline in familial frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2023, 19, 1947-1962.	0.4	0
383	C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. <i>Neurobiology of Disease</i> , 2022, 175, 105927.	2.1	3
384	Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study. <i>Journal of Neurology</i> , 0, , .	1.8	0
385	The role of neurofilament light in genetic frontotemporal lobar degeneration. <i>Brain Communications</i> , 2022, 5, .	1.5	6
386	PET/MR imaging of inflammation in atherosclerosis. <i>Nature Biomedical Engineering</i> , 2023, 7, 202-220.	11.6	10
387	Neurodevelopmental effects of genetic frontotemporal dementia in young adult mutation carriers. <i>Brain</i> , 0, , .	3.7	2
388	The Use of Executive Fluency Tasks to Detect Cognitive Impairment in Individuals with Subjective Cognitive Decline. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2022, 12, 491.	1.0	3

#	ARTICLE	IF	CITATIONS
389	White-matter abnormalities in presymptomatic <i>GRN</i> and <i>C9orf72</i> mutation carriers. <i>Brain Communications</i> , 2022, 5, .	1.5	1
390	Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2023, 60, 171-188.	2.7	2
391	Thalamic pathology in frontotemporal dementia: Predilection for specific nuclei, phenotype-specific signatures, clinical correlates, and practical relevance. <i>Brain and Behavior</i> , 2023, 13, .	1.0	4
392	Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	0
393	C9orf72 ALS mutation carriers show extensive cortical and subcortical damage compared to matched wild-type ALS patients. <i>NeuroImage: Clinical</i> , 2023, 38, 103400.	1.4	6
394	Addition of the FTD Module to the Neuropsychiatric Inventory improves classification of frontotemporal dementia spectrum disorders. <i>Journal of Neurology</i> , 0, , .	1.8	0
395	Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia. <i>Human Brain Mapping</i> , 2023, 44, 2684-2700.	1.9	4
396	Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia. <i>Brain</i> , 2023, 146, 3221-3231.	3.7	8
397	Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries. <i>JAMA Neurology</i> , 2023, 80, 279.	4.5	15
398	Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 187-218.	1.0	1
399	The Benson Complex Figure Test detects deficits in visuoconstruction and visual memory in symptomatic familial frontotemporal dementia: A GENFI study. <i>Journal of the Neurological Sciences</i> , 2023, 446, 120590.	0.3	0
400	Genetic forms of primary progressive aphasia within the GENetic Frontotemporal dementia Initiative (GENFI) cohort: comparison with sporadic primary progressive aphasia. <i>Brain Communications</i> , 2023, 5, .	1.5	5
401	Harnessing the potential of machine learning and artificial intelligence for dementia research. <i>Brain Informatics</i> , 2023, 10, .	1.8	8
402	Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study. <i>Neurobiology of Disease</i> , 2023, 179, 106068.	2.1	4
403	Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort. <i>Brain Communications</i> , 2023, 5, .	1.5	3
404	Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. <i>Brain</i> , 2023, 146, 2570-2583.	3.7	7
405	Accurate Bayesian segmentation of thalamic nuclei using diffusion MRI and an improved histological atlas. <i>NeuroImage</i> , 2023, 274, 120129.	2.1	3
416	Machine Learning for Alzheimer's Disease and Related Dementias. <i>NeuroMethods</i> , 2023, , 807-846.	0.2	1

#	ARTICLE	IF	CITATIONS
417	Longitudinal changes in qualitative aspects of semantic fluency in presymptomatic and prodromal genetic frontotemporal dementia. <i>Journal of Neurology</i> , 0, , .	1.8	0
419	Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit. <i>Neurology and Therapy</i> , 2023, 12, 1821-1843.	1.4	4
422	Unsupervised Heteromodal Physics-Informed Representation of MRI Data: Tackling Data Harmonisation, Imputation and Domain Shift. <i>Lecture Notes in Computer Science</i> , 2023, , 53-63.	1.0	0
427	Data-driven modelling of neurodegenerative disease progression: thinking outside the black box. <i>Nature Reviews Neuroscience</i> , 2024, 25, 111-130.	4.9	0